Clinical trial
Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
Recruiting now · Phase 2 · 1 countries · Registry ID NCT06691243
What this study is about
The purpose of this research study is to find out if semaglutide is safe and well tolerated in adults with cocaine use disorder who do and do not have human immunodeficiency virus (HIV). Participants will complete a screening process and if you are able to participate, you will be assigned to one of two treatment groups: semaglutide or placebo. Participants will: * Visit the clinic once a week for semaglutide or placebo injections * Visit the clinic once every two weeks for labwork, assessments and/or surveys * If consented to optional MRI's, complete two MRI's
Basic eligibility
Full registry criteria
Treatments and study arms
Semaglutide
The initial dose will be semaglutide 0.25mg which, if tolerated, will be escalated to 0.5mg. Escalation will continue to 1.0 mg and afterwards to 2.0 mg. The highest possible dose will be 2.0mg semaglutide.
Placebo
Patients randomized to placebo arm will receive placebo injection every week.
Primary outcomes
Number of Grade 3 and 4 adverse effects reported by patients at any time after Day 0
Dose of semaglutide the patient tolerates regardless of the presence of adverse effects
Study locations
2 locations were listed when this page was built. The first 40 are shown.